Prosecution Insights
Last updated: May 29, 2026
Application No. 18/076,613

FLUORINE-CONTAINING COMPOUND

Non-Final OA §OTHER§Other
Filed
Dec 07, 2022
Priority
Jun 10, 2020 — JP 2020-100920 +2 more
Examiner
SHTERENGARTS, SAMANTHA L
Art Unit
1623
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Daikin Industries Ltd.
OA Round
1 (Non-Final)
79%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
87%
With Interview

Examiner Intelligence

Grants 79% — above average
79%
Career Allowance Rate
1335 granted / 1681 resolved
+19.4% vs TC avg
Moderate +8% lift
Without
With
+7.9%
Interview Lift
resolved cases with interview
Fast prosecutor
2y 1m
Avg Prosecution
48 currently pending
Career history
1713
Total Applications
across all art units

Statute-Specific Performance

§101
1.4%
-38.6% vs TC avg
§103
18.5%
-21.5% vs TC avg
§102
24.1%
-15.9% vs TC avg
§112
22.0%
-18.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1681 resolved cases

Office Action

§OTHER §Other
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority The instant application is a continuation of national stage entry PCT/JP2021/021425, filed June 4, 2021. Acknowledgment is made of applicant's claim for foreign priority under 35 U.S.C. 119(a)-(d) by application no. JP2020-100920 filed in the Japanese Patent Office on June 10, 2020, which papers have been placed of record in the file. Information Disclosure Statement 4. The information disclosure statements (IDS) submitted on December 7, 2022; January 20, 2023; June 7, 2024l and March 24, 2206 were in compliance with the provisions of 37 CFR 1.97 and 37 CFR 1.98. The IDS documents were considered. A signed copy of each form 1449 is enclosed herewith. Election/Restrictions 5. Applicant’s election without traverse of Group I in the reply filed on September 30, 2025 is acknowledged. Upon further consideration, the restriction requirement is withdrawn and all claims are rejoined. Status of Claims 6. Claims 1-16 are pending and under consideration in the instant application. Claim Rejections – Improper Markush Group 7. The nonstatutory Markush grouping rejection is based on a judicially approved “improper Markush grouping” doctrine. Claims 1-16 are rejected on the judicially-created basis that it contains an improper Markush grouping of alternatives. See In re Harnisch, 631 F.2d 716, 721-22 (CCPA 1980) and Ex parte Hozumi, 3 USPQ2d 1059, 1060 (Bd. Pat. App. & Int. 1984). The improper Markush grouping includes species of the claimed invention that do not share both a substantial structural feature and a common use that flows from the substantial structural feature. A Markush claim contains an “improper Markush grouping” if: (1) The species of the Markush group do not share a single structural similarity,” or (2) the species do not share a common use. Members of a Markush group share a "single structural similarity” when they belong to the same recognized physical or chemical class or to the same recognized physical or chemical class or to the same art-recognized class. Members of a Markush group share a common use when they are disclosed in the specification or known in the art to be functionally equivalent (see Federal Register, Vol. 76, No. 27, Wednesday, February 9, 2011, p. 7166, left and middle columns, bridging paragraph). In the present case, at least (1) applies. It cannot be said that all members of the Markush group have a single structural similarity from which the activity flows. Specifically, the species of the Markush group do not share a “single structural similarity” because there are no required structural features within the compounds of formula 1, such that each member of the group would have at least one structural feature, which feature is essential to the activity/function of the claimed compounds, in common. In addition, at least (2) applies since each alternatively usable member of the Markush group does not share a common use. Rather, the specification discloses that the compounds are useful as textile products; however, there is no common core in the compounds of formula 1 that are known as textile products as well as water- and oil- repellent agents. It is suggested that applicant amend the claims to contain only proper Markush groupings to compounds sharing a single structural similarity and a common use, wherein the common use shared by the compounds is a result of the structural similarity essential to the function of the compounds. The question of whether the lack of a specific statutory basis is a fatal flaw against a holding of an Improper Markush group was decided in In re Harnish, 206 USPQ 300, 305, where the court said, “…we think it should be clear from our actions in Weber and Haas II that we there recognized the possibility of such a thing as an "improper Markush grouping." We were and are aware that it does not have a specific statutory basis …” The court went on to reverse the rejection, (which had been made by the Board under Rule 196(b)) but not on the lack of a specific statutory basis but rather, “Clearly, they are all coumarin compounds which the board admitted to be "a single structural similarity." We hold, therefore, that the claimed compounds all belong to a subgenus, as defined by appellant, which is not repugnant to scientific classification. Under these circumstances we consider the claimed compounds to be part of a single invention so that there is unity of invention…” Thus, the rejection was overturned not because of any lack of a specific statutory basis, but because of the specific facts in the case. The Markush group was held proper in that case, as was the case also in Ex parte Price 150 USPQ 467, Ex parte Beck and Taylor, 119 USPQ 100, and Ex parte Della Bella and Chiarino 7 USPQ2d 1669. Cases where the Markush group was held improper include Ex Parte Palmer, 7 USPQ 11, In re Winnek, 73 USPQ 225, In re Ruzicka, 66 USPQ 226, Ex parte Hentrich, 57 USPQ 419, Ex parte Barnard, 135 USPQ 109, Ex parte Reid, 105 USPQ 251, Ex parte Sun and Huggins, 85 USPQ 516, In re Thompson and Tanner, 69 USPQ 148, In re Swenson, 56 USPQ 180, and In re Kingston, 65 USPQ 371. Note In re Milas 71 USPQ 212 in which the structural difference between vitamin A and D was sufficient to uphold the improper Markush rejection. Also see In re Winnek 73 USPQ 225 and In re Ruzicka 66 USPQ 226 in which structural differences were small and yet a similar holding was maintained. All these cases involved compounds in the pharmaceutical art known to be structure-sensitive. Of particular interest is Ex Parte Hozumi, 3 USPQ2d 1059, which reversed an improper Markush rejection “in view of the relatively large proportion of the structure of the compounds in the claimed class which is common to the entire class.” Here, by contrast, the amount in common is none, relative to the entire molecule. In response to this rejection, Applicant should either amend the claim(s) to recite only individual species or grouping of species that share a substantial structural feature as well as a common use that flows from the substantial structural feature, or present a sufficient showing that the species recited in the alternative of the claims(s) in fact share a substantial structural feature as well as a common use that flows from the substantial structural feature. This is a rejection on the merits and may be appealed to the Board of Patent Appeals and Interferences in accordance with 35 U.S.C. §134 and 37 CFR 41.31(a)(1) (emphasis provided). Allowable Subject Matter 8. Compounds of formula (1) are free of the prior art. The closest prior art is as follows: Castelvetro, V et al. Adapting the Properties of New Fluorinated Acrylic Polymers to Suit the Conservation of Ancient Monuments, Surface Coatings International. 1998, vol. 81, no. 11, pp 551-556. Teaches 1,1,2,2-perfluorodecyl-methacrylate PNG media_image1.png 142 469 media_image1.png Greyscale which lacks the claimed R1 group. JP 2003-193370 Teaches compounds of formulae PNG media_image2.png 474 414 media_image2.png Greyscale which lacks the claimed R2 group. WO 2013/058335 Teaches compounds of pages 6-9 which lacks the claimed R2 group. Conclusion 9. No claims allowed. 10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Samantha Shterengarts whose telephone number is (571)270-5316. The examiner can normally be reached on Monday thru Thursday 9-6pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Mr. Adam Milligan can be reached on 571-270-7674. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SAMANTHA L SHTERENGARTS/Primary Examiner, Art Unit 1623
Read full office action

Prosecution Timeline

Dec 07, 2022
Application Filed
May 13, 2026
Non-Final Rejection mailed — §OTHER, §Other (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12617759
MODIFIER OF FOUR-MEMBERED RING DERIVATIVE, PREPARATION METHOD AND APPLICATION THEREOF
4y 0m to grant Granted May 05, 2026
Patent 12606529
SULFUR AND AMIDE TROPOLONE INHIBITORS OF NUCLEOTIDYL TRANSFERASES AND USES THEREFOR
4y 5m to grant Granted Apr 21, 2026
Patent 12606526
SUBSTITUTED SALICYLAMIDE COMPOUNDS AND USE THEREOF
2y 9m to grant Granted Apr 21, 2026
Patent 12600723
TETRACYCLIC COMPOUNDS AS DGK INHIBITORS
2y 9m to grant Granted Apr 14, 2026
Patent 12599547
TOPICAL COMPOSITIONS OPTIMISED FOR EPIDERMAL LIPIDS AND PHOSPHATIDYL GYCEROL
2y 8m to grant Granted Apr 14, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
79%
Grant Probability
87%
With Interview (+7.9%)
2y 1m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1681 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month